Genzyme to Purchase new Cancer Drug from AstraZeneca

New England Council member Genzyme has announced an agreement with AstraZeneca in which Genzyme will purchase a cancer therapy drug for $300 million.

The drug is called Caprelsa and it is used to treat a specific type of thyroid cancer. The drug is also in Phase III research for treatment of another type of cancer. The deal allows Genzyme—a leader in endocrinology– to sell and further develop Caprelsa.

Genzyme President and CEO David Meeker, M.D., explained, “The addition of the Caprelsa represents a strong strategic fit for our rare Endocrinology portfolio and underscores Genzyme’s commitment to addressing unmet needs in the thyroid community. We look forward to bringing our rare disease expertise to appropriate patients with advanced stage thyroid carcinoma.”

The New England Council congratulates Genzyme on this acquisition and commends the company for it’s commitment to treating rare diseases.

For more information, see Genzyme’s press release, or this Boston Globe article.

Recently from the Blog

This fall, The New England Council will launch a new virtual event series called “Inside the Corner Office.”

07/26/2021 | Read Post

New England College finds success in recruiting diverse student body

07/23/2021 | Read Post

In the News

NEC Board Elects Three New Directors

04/27/2021 | Read Press Release

NEC Endorses Cannabis Banking Legislation

04/1/2021 | Read Press Release